David Fox
FDA’s Proposed New Pathway for Devices Referencing Drugs (DRDs)
Focus on Regulation ·
FDA Clarifies and Expands Eligibility for RMAT Designation for Gene Therapies
Focus on Regulation ·
Supreme Court Issues Landmark Biosimilar Ruling
Biosimilars Law Blog ·
Just in Time: FDA Finalizes Guidance on Assessment of Abuse Potential of Drugs
Focus on Regulation ·